nirsevimab
AZ, Sanofi get first green light for RSV prophylactic antibody
Phil Taylor
antibody, AstraZeneca, Beyfortus, nirsevimab, paediatrics, prevention, respiratory syncytial virus, Sanofi
0 Comment
CHMP says yes to Sanofi/AstraZeneca antibody for RSV prevention
Phil Taylor
antibody, AstraZeneca, Beyfortus, CHMP, GlaxoSmithKline, nirsevimab, Pfizer, respiratory syncytial virus, Sanofi
0 Comment
AZ, Sanofi build case for one-shot RSV antibody
Phil Taylor
AstraZeneca, infectious disease, nirsevimab, paediatrics, respiratory syncytial virus, Sanofi
0 Comment
After GSK stumble, Pfizer moves forward with RSV vaccine
Phil Taylor
AstraZeneca, GlaxoSmithKline, nirsevimab, Pfizer, respiratory syncytial virus, Sanofi, SOBI, Synagis, vaccine
0 Comment
AZ, Sanofi prep filings for one-shot RSV antibody after trial win
Phil Taylor
AstraZeneca, GlaxoSmithKline, nirsevimab, respiratory syncytial virus, Sanofi, SOBI, Synagis, vaccine
0 Comment